{
    "xml": "<topic id=\"PHP5787\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/abiraterone-acetate\" basename=\"abiraterone-acetate\" title=\"ABIRATERONE ACETATE\">\n<title>ABIRATERONE ACETATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1213\" namespace=\"/interactions/list-of-drug-interactions/hormone-antagonists/abiraterone\">Abiraterone</xref>\n</p>\n<data name=\"vtmid\">19528811000001106</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_677939183\" title=\"Anti-androgens\">Anti-androgens</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP51410\" outputclass=\"indicationsAndDose\" rev=\"1.24\" parent=\"/drugs/abiraterone-acetate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with a docetaxel-containing chemotherapy regimen (in combination with prednisone or prednisolone)</p>\n<p outputclass=\"therapeuticIndication\">Metastatic castration-resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (in combination with prednisone or prednisolone)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g once daily, for dose of concurrent prednisone or prednisolone&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51494\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/abiraterone-acetate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diabetes (increased risk of hyperglycaemia&#8212;monitor blood sugar frequently)</ph>; <ph outputclass=\"caution\">history of cardiovascular disease</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Cardiovascular disease</p>\n<p>Correct hypertension and hypokalaemia before treatment (if significant risk of congestive heart failure, such as history of cardiac failure, uncontrolled hypertension or cardiac events, consult product literature for management and increased monitoring).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51398\" outputclass=\"interactions\" rev=\"1.12\" parent=\"/drugs/abiraterone-acetate\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (abiraterone).</p>\n<p>Caution with concurrent chemotherapy&#8212;safety and efficacy not established.</p>\n<p>Caution with concomitant use of drugs known to be associated with myopathy or rhabdomyolysis.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51352\" outputclass=\"sideEffects\" rev=\"1.17\" parent=\"/drugs/abiraterone-acetate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angina</ph>; <ph outputclass=\"sideEffect\">arrhythmia</ph>; <ph outputclass=\"sideEffect\">atrial fibrillation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">fractures</ph>; <ph outputclass=\"sideEffect\">haematuria</ph>; <ph outputclass=\"sideEffect\">heart failure</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypertriglyceridaemia</ph>; <ph outputclass=\"sideEffect\">hypokalaemia</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">sepsis</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>; <ph outputclass=\"sideEffect\">urinary tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Adrenal insufficiency</ph>; <ph outputclass=\"sideEffect\">myopathy</ph>; <ph outputclass=\"sideEffect\">rhabdomyolysis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Allergic alveolitis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51488\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/abiraterone-acetate\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Men should use condoms if their partner is pregnant, and use condoms in combination with another effective contraceptive method if their partner is of child-bearing potential&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51429\" outputclass=\"hepaticImpairment\" parent=\"/drugs/abiraterone-acetate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution in moderate impairment and only if benefit clearly outweighs risk.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51368\" outputclass=\"renalImpairment\" parent=\"/drugs/abiraterone-acetate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution in severe impairment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51337\" outputclass=\"monitoringRequirements\" parent=\"/drugs/abiraterone-acetate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor blood pressure, serum potassium concentration, and fluid balance before treatment, and at least monthly during treatment&#8212;consult product literature for management of hypertension, hypokalaemia and oedema.</p>\n<p>Monitor liver function before treatment, then every 2 weeks for the first 3 months of treatment, then monthly thereafter&#8212;interrupt treatment if serum alanine aminotransferase or aspartate aminotransferase greater than 5 times the upper limit (consult product literature for details of restarting treatment at a lower dose) and discontinue permanently if 20 times the upper limit.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51326\" outputclass=\"nationalFunding\" rev=\"1.20\" parent=\"/drugs/abiraterone-acetate\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA259</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (June 2012)</p>\r\n<p>Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration-resistant metastatic prostate cancer only if:</p>\r\n<ul>\r\n<li>their disease has progressed on or after one docetaxel-containing chemotherapy regimen, <b>and</b>\r\n</li>\r\n<li>the manufacturer provides abiraterone with the discount agreed in the patient access scheme.</li>\r\n</ul>\r\n<p>Patients currently receiving abiraterone in combination with prednisone or prednisolone whose disease does not meet the first criteria should be able to continue therapy until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA259\">www.nice.org.uk/TA259</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (July 2012) that abiraterone (<i>Zytiga</i>\r\n<tm tmtype=\"reg\"/>), in combination with prednisone or prednisolone, is accepted for restricted use within NHS Scotland for the treatment of metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with docetaxel-containing chemotherapy regimen, and have received only one prior chemotherapy regimen.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5787-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/abiraterone-acetate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75026\" title=\"Tablet\" namespace=\"/drugs/abiraterone-acetate/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78591\" namespace=\"/treatment-summaries/hormones-malignant-disease\" title=\"Hormones, malignant disease\" count=\"2\" rel=\"backlink\">Hormones, malignant disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1213\" namespace=\"/interactions/list-of-drug-interactions/hormone-antagonists/abiraterone\" title=\"Abiraterone\" count=\"1\" rel=\"link\">Abiraterone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75026\" namespace=\"/drugs/abiraterone-acetate/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP5787",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/abiraterone-acetate",
    "basename": "abiraterone-acetate",
    "title": "ABIRATERONE ACETATE",
    "interactants": [
        {
            "id": "bnf_int_1213",
            "label": "Abiraterone"
        }
    ],
    "vtmid": "19528811000001106",
    "drugClassification": [
        "Anti-androgens"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with a docetaxel-containing chemotherapy regimen (in combination with prednisone or prednisolone)",
                        "html": "Metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with a docetaxel-containing chemotherapy regimen (in combination with prednisone or prednisolone)"
                    },
                    {
                        "textContent": "Metastatic castration-resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (in combination with prednisone or prednisolone)",
                        "html": "Metastatic castration-resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (in combination with prednisone or prednisolone)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1 g once daily, for dose of concurrent prednisone or prednisolone&#8212;consult product literature.",
                        "html": "<p>1&#8239;g once daily, for dose of concurrent prednisone or prednisolone&#8212;consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diabetes (increased risk of hyperglycaemia&#8212;monitor blood sugar frequently)",
                "html": "Diabetes (increased risk of hyperglycaemia&#8212;monitor blood sugar frequently)"
            },
            {
                "type": "cautions",
                "textContent": "history of cardiovascular disease",
                "html": "history of cardiovascular disease"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Cardiovascular disease",
                "textContent": "Correct hypertension and hypokalaemia before treatment (if significant risk of congestive heart failure, such as history of cardiac failure, uncontrolled hypertension or cardiac events, consult product literature for management and increased monitoring).",
                "html": "<p>Correct hypertension and hypokalaemia before treatment (if significant risk of congestive heart failure, such as history of cardiac failure, uncontrolled hypertension or cardiac events, consult product literature for management and increased monitoring).</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (abiraterone).\n\nCaution with concurrent chemotherapy&#8212;safety and efficacy not established.\n\nCaution with concomitant use of drugs known to be associated with myopathy or rhabdomyolysis.",
                "html": "<p>Appendix 1 (abiraterone).</p><p>Caution with concurrent chemotherapy&#8212;safety and efficacy not established.</p><p>Caution with concomitant use of drugs known to be associated with myopathy or rhabdomyolysis.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Angina",
                        "html": "Angina",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arrhythmia",
                        "html": "arrhythmia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "atrial fibrillation",
                        "html": "atrial fibrillation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fractures",
                        "html": "fractures",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haematuria",
                        "html": "haematuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "heart failure",
                        "html": "heart failure",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatotoxicity",
                        "html": "hepatotoxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertriglyceridaemia",
                        "html": "hypertriglyceridaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypokalaemia",
                        "html": "hypokalaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sepsis",
                        "html": "sepsis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary tract infection",
                        "html": "urinary tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Adrenal insufficiency",
                        "html": "Adrenal insufficiency",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "myopathy",
                        "html": "myopathy",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rhabdomyolysis",
                        "html": "rhabdomyolysis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Allergic alveolitis",
                        "html": "Allergic alveolitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Men should use condoms if their partner is pregnant, and use condoms in combination with another effective contraceptive method if their partner is of child-bearing potential&#8212;toxicity in animal studies.",
                "html": "<p>Men should use condoms if their partner is pregnant, and use condoms in combination with another effective contraceptive method if their partner is of child-bearing potential&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution in moderate impairment and only if benefit clearly outweighs risk.\n\nAvoid in severe impairment.",
                "html": "<p>Use with caution in moderate impairment and only if benefit clearly outweighs risk.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution in severe impairment&#8212;no information available.",
                "html": "<p>Use with caution in severe impairment&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor blood pressure, serum potassium concentration, and fluid balance before treatment, and at least monthly during treatment&#8212;consult product literature for management of hypertension, hypokalaemia and oedema.\n\nMonitor liver function before treatment, then every 2 weeks for the first 3 months of treatment, then monthly thereafter&#8212;interrupt treatment if serum alanine aminotransferase or aspartate aminotransferase greater than 5 times the upper limit (consult product literature for details of restarting treatment at a lower dose) and discontinue permanently if 20 times the upper limit.",
                "html": "<p>Monitor blood pressure, serum potassium concentration, and fluid balance before treatment, and at least monthly during treatment&#8212;consult product literature for management of hypertension, hypokalaemia and oedema.</p><p>Monitor liver function before treatment, then every 2 weeks for the first 3 months of treatment, then monthly thereafter&#8212;interrupt treatment if serum alanine aminotransferase or aspartate aminotransferase greater than 5 times the upper limit (consult product literature for details of restarting treatment at a lower dose) and discontinue permanently if 20 times the upper limit.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA259",
                        "label": "www.nice.org.uk/TA259"
                    }
                ],
                "fundingIdentifier": "NICE TA259",
                "textContent": "Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (June 2012) Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration-resistant metastatic prostate cancer only if: their disease has progressed on or after one docetaxel-containing chemotherapy regimen, and the manufacturer provides abiraterone with the discount agreed in the patient access scheme. Patients currently receiving abiraterone in combination with prednisone or prednisolone whose disease does not meet the first criteria should be able to continue therapy until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA259",
                "html": "<p outputclass=\"title\">Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (June 2012)</p> <p>Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration-resistant metastatic prostate cancer only if:</p> <ul> <li>their disease has progressed on or after one docetaxel-containing chemotherapy regimen, <b>and</b> </li> <li>the manufacturer provides abiraterone with the discount agreed in the patient access scheme.</li> </ul> <p>Patients currently receiving abiraterone in combination with prednisone or prednisolone whose disease does not meet the first criteria should be able to continue therapy until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA259\">www.nice.org.uk/TA259</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75026",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78591",
                "label": "Hormones, malignant disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1213",
                "label": "Abiraterone",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75026",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}